US4310518A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cyclic hexapeptide somatostatin analogs
Assignee: Merck and Co Inc
•
Filing: 1980-10-01
•
Granted: 1982-01-12
•
Expires: 2000-10-01
Abstract
Abstract Somatostatin analogs are prepared wherein a cyclic hexapeptide contains a secondary amino acid which replaces seven of the ring amino acids of somatostatin. The cyclic hexapeptides are easier to synthesize, have a longer duration of activity, and many have a greater level of activity than somatostatin. The compounds have the properties of inhibiting the release of glucagon, growth hormone and insulin. Certain of the compounds also are capable of inhibiting the release of gastric acid secretions. The compounds are particularly useful in the treatment of acromegaly, diabetes, diabetic retinopathy and peptic ulcers. These cyclic hexapeptides are prepared by the solid phase method.
Inventors
- 👤 Roger M. Freidinger
- 👤 Daniel F. Veber
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 14:23
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/655; C07K14/6555; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/16
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
121 words
A compound having the formula: ##STR15## wherein Y is (CH 2 ) m wherein m is 0, 1 or 2 or sulfur; R 1 and R 2 are independently lower alkyl, benzyl, substituted benzyl wherein the substituent may be one or two of loweralkyl, halogen, hydroxy, amino, nitro or loweralkoxy; and loweralkyl substituted with a 5- or 6-membered heterocyclic ring; R 3 is 3-indolylmethyl or substituted 3-indolylmethyl wherein the substituent may be loweralkyl, loweralkoxy or halogen; R 4 is loweralkyl, hydroxyloweralkyl, benzyl, carboxyloweralkyl, aminoloweralkyl or substituted hydroxy benzyl wherein the substituent may be loweralkyl, loweralkoxy, hydroxy, halogen, amino or nitro; and R 5 is hydrogen, loweralkyl, benzyl, or substituted benzyl wherein the substituent is loweralkyl, loweralkoxy, hydroxy, halogen, amino or nitro.
Claim 2
Dependent Claim
121 words
A compound having the formula: ##STR15## wherein Y is (CH 2 ) m wherein m is 0, 1 or 2 or sulfur; R 1 and R 2 are independently lower alkyl, benzyl, substituted benzyl wherein the substituent may be one or two of loweralkyl, halogen, hydroxy, amino, nitro or loweralkoxy; and loweralkyl substituted with a 5- or 6-membered heterocyclic ring; R 3 is 3-indolylmethyl or substituted 3-indolylmethyl wherein the substituent may be loweralkyl, loweralkoxy or halogen; R 4 is loweralkyl, hydroxyloweralkyl, benzyl, carboxyloweralkyl, aminoloweralkyl or substituted hydroxy benzyl wherein the substituent may be loweralkyl, loweralkoxy, hydroxy, halogen, amino or nitro; and R 5 is hydrogen, loweralkyl, benzyl, or substituted benzyl wherein the substituent is loweralkyl, loweralkoxy, hydroxy, halogen, amino or nitro.
Claim 3
Dependent Claim
58 words
A compound of claim 1 wherein Y is (CH 2 ) n and n is 1; R 1 and R 2 are as defined in claim 1; R 3 is 3-indolylmethyl or substituted indolylmethyl wherein the substituent is methoxy or fluoro; R 4 is methyl, ethyl, hydroxymethyl or hydroxyethyl; and R 5 is as defined in claim 1.
Claim 4
Dependent Claim
10 words
A compound of claim 2 wherein R 5 is methyl.
Claim 5
Dependent Claim
22 words
A compound of claim 3 wherein: Y is methylene; R 3 is 3-indolylmethyl; R 4 is hydroxyethyl; and R 5 is methyl.
Claim 6
Dependent Claim
9 words
The compound of claim 2 which is cyclo (N-Me-Ala-Try-D-Trp-Lys-Thr-Phe).
Claim 7
Dependent Claim
9 words
The compound of claim 2 which is cyclo (N-Me-D-Ala-Tyr-D-Trp-Lys-Thr-Phe).
Claim 8
Dependent Claim
8 words
The compound of claim 2 which is Cyclo-(N-Me-Ala-Phe-D-Trp-Lys-Val-Phe).
Claim 9
Dependent Claim
8 words
The compound of claim 2 which is Cyclo-(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe).
Claim 10
Dependent Claim
25 words
A method for inhibiting the release of growth hormone which comprises administering to an animal an effective amount of a cyclic hexapeptide of claim 1.
Claim 11
Dependent Claim
43 words
A pharmaceutical composition for use in the treatment of acromegaly, diabetes, diabetic retinopathy, and peptic ulcers comprising a therapeutically effective amount of the cyclic hexapeptide of claim 1 or the nontoxic acid addition salts thereof in a pharmaceutically acceptable liquid or solid carrier.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-01-11 | 1985-07-13 | 1986-01-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-01-11 | 1989-07-13 | 1990-01-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-01-11 | 1993-07-13 | 1994-01-12 | $7700.00 | Window Closed / Lapsed |